Meridian Bioscience, Inc.
Bioline Launches the Full Range of EPIK™ miRNA Assays
CINCINNATI, 2017-01-09 18:12 CET (GLOBE NEWSWIRE) --
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the expansion of the EPIK™ miRNA Select Assays, originally developed for the study of individual microRNA (miRNA) molecules. In collaboration with MiRXES, Bioline released 800 EPIK™ miRNA Select Assays in March 2016 and this has now been increased to include all of the organisms listed on the miRBase release 21, which represents over 27,000 miRNA assays. Recent studies continue to show the clinical value of individual miRNA molecules which are released from tissues and cells. The expression of certain individual miRNA molecules correlates with specific disease conditions making them promising biomarker candidates for the early detection of disease, prognosis and monitoring of treatment in both humans and other organisms.
Each assay is designed by MiRXESin silicousing proprietary thermodynamics-based algorithms and include miRNA specific reverse transcriptase primers and hemi-nested real-time PCR primers along with Bioline reverse transcriptase, SensiSMART™ with SYBR®1Green and highly optimized buffers. The resulting assays enable detection of extremely low levels of miRNA with very high specificity and allow the discrimination between closely related miRNA sequences.
Marco Calzavara, President of Bioline commented, “I am very pleased to announce the expansion of the EPIK miRNA Select Assays. The increased portfolio of high quality miRNA assays will help even more researchers with miRNA expression profiling, quantification and in biomarker discovery.”
Richard L. Eberly, President, Chief Commercial Officer, stated, “The release of the full range of EPIK miRNA Select Assays and their enhanced performance are an important addition to our portfolio. They increase the flexibility of this highly useful research tool by allowing more of our life science customers to create accurate and non-invasive molecular diagnostic assays in humans and in other organisms.”
About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agribio industries engaged in research and by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agribio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website address iswww.meridianbioscience.com.
FOR ADDITIONAL INFORMATION:
For more information about Bioline, please visithttp://www.bioline.com.
1SYBR is a registered trademark of Thermo Fisher Scientific.
Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Tier1CRM11.12.2017 23:31 | pressemeddelelse
Tier1CRM Receives Significant Equity Capital to Accelerate Growth
Minerva Neurosciences, Inc.11.12.2017 22:42 | pressemeddelelse
Minerva Neurosciences Names Richard Russell President
Sonoco Products Company11.12.2017 22:31 | pressemeddelelse
Sonoco-Alcore to Increase Paperboard Prices in Europe
Minerva Neurosciences, Inc.11.12.2017 14:17 | pressemeddelelse
Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors
Sabina Gold & Silver Corp.11.12.2017 13:31 | pressemeddelelse
Sabina Gold & Silver Announces Commencement of the Review of its Water License Applications for the Back River Project
Standard Lithium Ltd.11.12.2017 11:02 | pressemeddelelse
Standard Lithium Provides Development Update on California Lithium Project
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum